AB0058 Il2 decrease and increase of il10 and inf1a are associated to clinical activity in systemic lupus erythematouspatients

Abstract

BackgroundSystemic lupus erythematous (SLE) is an autoimmune disease characterised by deregulation of cytokine production. INF1A is a proinflamatory cytokine considered as a key molecule in the SLE etiopathogenesis, being responsible indirectly of IL10 upregulation. BLyS is involved in autoantibodies production and clinical activity in SLE, and its expression is regulated by other cytokines as IL10 and INF1A. IL2 is an anti-inflammatory cytokine in SLE, but its loss leads to the production of Th2 proinflammatory cytokines as IL4, IL5 and IL13.ObjectivesTo analyse the association among inflammatory cytokine levels and clinical activity, as well as to identify a cytokine profile related to disease activity in SLE.MethodsA cross-sectional, observational study of 142 patients diagnosed of SLESLICC 2012 criteria), and 35 healthy controls, was performed. A complete blood-test and an interview were carried out to collect their clinical data. We analysed inflammatory cytokines serum levels by colorimetric methods. Biostatistical analysis with R was performed.ResultsMean cytokine levels for the SLE patients and healthy controls are shown in the table 1.Abstract AB0058 – Table 1SLE patients (pg/mL)Mean (SD)Healthy controls (pg/mL)Mean (SD) IL24.34 (12.2)4,964,5IL458.65 (64.6)89,0570,18IL518 (5.71)7,338,59IL1012.29 (32.82)1,923,67IL1344.97 (273.78)42,8593,05IL213.18 (5.61)2,823,35INF1A15.69 (24.59)4,841,91BLyS2293.82 (6948.46)1181,15260,04The mean clinical activity measured by SLEDAI was 5.91±5.06, and we observed a statistically significant association between high levels of IL10 and high clinical activity (p=0.001).Statistical analysis indicates that complement consumption is associated with increased levels of IL10 (p=0.029), INF1A (p<0.001), IL4 (p=0.004), IL5 (p=0.009) and decreased levels of IL2 (p=0.045),; or anti-DNA positivity is associated with increased levels of INF1A (p=0.002) and decreased levels of IL2 (p=0.045), IL4 (p=0.034) and IL5 (p=0.007).Moreover, BLyS seems to have increased in patients with positive antiphospholipid antibodies and anti-DNA. IL10 is associated with ENAs positivity (p=0.022). In patients with other autoimmune disease associated with SLE, an increase of INF1A (p=0.008) and IL5 (p=0.044) is observed.SLE patients were categorised by normal, low or high level of the eight citokines. Despite the fact that no specific cytokine profile associated with clinical activity was observed, those patients with high SLEDAI score had increased levels of IL10 and INF1A and decreased levels of IL2 and IL21.ConclusionsOur SLE patients displayed mainly IL10, INF1A and BLyS increased, and IL2 decreased. Although IL10 seems to be the cytokine which best fits to clinical activity in SLE, altered levels of INF1A, IL2, IL4, and IL5 are associated with complement consumption or anti-DNA positivity.Disclosure of InterestNone declared